Brainjo, based in Regensburg, has closed a €2 million seed round led by High-Tech Gründerfonds (HTGF), with angel investors like Andreas Weinhut and better ventures also joining. The money will go toward clinical studies and getting regulatory approval for the company’s first product, a VR-based digital health app (DiGA) for children with ADHD.
In Germany, children often wait months for mental health care: therapy spots are scarce, and access varies. Families dealing with ADHD still face a big gap between diagnosis and real help. While some apps can help, brainjo’s virtual reality offers a meaningful, immersive treatment that kids can use at home.
Brainjo was founded in 2022 by Markus Wensauer and Christian Gnerlich. They built their platform in partnership with MEDICE, a leading European pharmaceutical company specialising in ADHD medication. The partnership goes beyond just distribution and fits with MEDICE’s move into broader care, where brainjo’s VR therapy plays an important role.
The platform turns proven therapy content, including tasks such as homework, into virtual environments where children can practice coping skills in a fun, structured way. A reward system helps keep kids engaged over time.
Brainjo says this kind of immersion makes its product stand out from other DiGA software, such as Brainhero and app-based training tools, which do not offer the same level of clinical engagement as VR.
“What differentiates brainjo from purely software-based solutions is the depth of immersion enabled by Virtual Reality, a clinically relevant approach that we will substantiate with study data and use to improve adherence,” says Dr Jörg Traub, principal at HTGF.
Looking ahead, Brainjo aims to be listed as a DiGA, Germany’s system for digital health apps that doctors can prescribe and that insurance can cover. They hope to get market approval by 2028. A clinical study with about 100 children with ADHD is already in progress.
